Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

At 5 years, adjuvant nivolumab improved disease-free survival versus placebo (HR 0.74). In a post hoc Signatera analysis the disease-free survival HR was 0.35 if baseline ctDNA was detectable and 0.99 if it was not.

Annals of OncologyPubMed 41110694DOI 10.1016/j.annonc.2025.09.139